{"id":"W2967350775","doi":"10.1016/s1470-2045(19)30413-9","title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":780,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; University of Calgary","funders":"Cilag; Foundation Medicine; Pharmacyclics; EMD Serono; Genentech; Astellas Pharma; Eisai; Jounce Therapeutics; Acceleron; Chugai Pharmaceutical; Horizon Pharma; National Cancer Institute; Intuitive Surgical; Gilead Sciences; Calithera Biosciences; Celldex Therapeutics; Ipsen; Array BioPharma; Center for Outcomes Research and Evaluation, Yale School of Medicine; Bayer HealthCare; Society of Memorial Sloan Kettering; Exelixis; Sanofi; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; EUSA Pharma; AstraZeneca; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Agilent Technologies; Amgen; Pfizer","keywords":"Nivolumab; Sunitinib; Ipilimumab; Medicine; Renal cell carcinoma; Internal medicine; Oncology; Carcinoma; First line; Randomized controlled trial; Clinical trial; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008401435,0.0003750972,0.002583675,0.0001230671,0.00008280694,0.000008682581,0.0001802875,0.000211921,0.00007340914],"category_scores_gemma":[0.0005563169,0.0002355709,0.0003434588,0.0001379321,0.0001526529,0.00004555048,0.00005919308,0.0002229861,0.0000118925],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000909349,"about_ca_system_score_gemma":0.0005253733,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005397053,"about_ca_topic_score_gemma":0.000841362,"domain_scores_codex":[0.9971778,0.0004406694,0.001039327,0.0005833267,0.0002303562,0.0005285353],"domain_scores_gemma":[0.9916437,0.00677834,0.0005365679,0.0007737587,0.000122891,0.0001446948],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9803102,0.001892762,0.00004130899,0.00005538276,0.0003673571,0.0001122323,0.001468691,0.000170864,0.004216969,0.00003534974,0.0001344722,0.01119441],"study_design_scores_gemma":[0.9404457,0.04623474,0.000759444,0.00006230445,0.001050778,0.00001478,0.000314319,0.001095534,0.005368566,0.00005487749,0.004415992,0.0001829728],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9801894,0.001305052,0.00003034802,0.001452234,0.0008071237,0.01125641,0.0004651521,0.00003182385,0.004462462],"genre_scores_gemma":[0.9956458,0.0004472919,0.0006269198,0.00007693384,0.0005863584,0.0007758642,0.0005426728,0.00003808766,0.001260066],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04434197,"threshold_uncertainty_score":0.9606303,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06296786444902643,"score_gpt":0.3424189717806109,"score_spread":0.2794511073315845,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}